Download Molludab (5% potassium hydroxide solution)

NHS Corby Clinical Commissioning Group
Kettering General Hospital NHS Trust NHS Nene
Clinical Commissioning Group Northampton General
Hospital NHS Trust Northamptonshire Healthcare
NHS Foundation Trust
NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP
(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers
on prescribing across the county)
Summary of Recommendations from meeting on
Wednesday 21 August 2013
• Molludab (5% potassium hydroxide solution)
Topical treatment for viral skin infection molluscum contagiosum. In healthy patients this
condition clears up in 12-18 months so usual recommendation is not to treat.
Categorised as DOUBLE RED.
• Colobreathe (Colistimethate sodium dry powder inhaler)
Specialised commissioning (NHS England) is responsible for cystic fibrosis so categorised as
RED.
• Emustil (Soybean oil eye drops)
Guidance is being produced on eye lubricants with the ophthalmologists. Categorised GREY
pending guidance.
• Renavit
Vitamin supplement for patients on dialysis (specialised commissioning) so categorised RED.
• Nipatra (chewable sildenafil)
For treatment of erectile dysfunction. No obvious benefit for this preparation over sildenafil tablets
but it will be considerably more expensive as generic sildenafil is now available.
Categorised as DOUBLE RED.
• Cold sore light treatment
Trial information for the use of light treatment for cold sores is limited. Several products available
(retail ~ £30) but one product Virulite £18.50 is listed in the Drug Tariff.
Categorised as DOUBLE RED.
• Fluoride toothpaste and mouthwash
Opinion was they should be prescribed by dentists only. Categorised as DOUBLE RED.
•
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar
disorder NICE TA292
Categorised as RED for this indication for these patients.
• Dapagliflozin in combination therapy for treating type 2 diabetes NICE TA288
Categorisation changed from DOUBLE RED to GREEN when prescribed in accordance with
NICE Guidance (see link above)
• Antiplatelet guidance
The updated guidance was approved and is available on Pathfinder antiplatelet guidelines
• Guideline for the Treatment and Prophylaxis of vitamin D deficiency in children and
adolescents
The guidance was approved and is available on Pathfinder vitamin-d-in-children
• Prescribing Guidelines for infant formula relating to CMPA or lactose intolerance.
Due to difficulties in implementation advice in this guidance concerning lactose-free formulas
SMA and Infamil lactose free were categorised as DOUBLE RED.
Further information or clinical trial data may be obtained from the CCG Prescribing Advisers or Hospital Medicines Information Service.
Information in this bulletin is believed to be true and accurate. The NHS and their employees accept no liability for loss of any nature, to persons,
organisations or institutions that may arise as a result of any errors or omissions.